Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer (NCT04502407)
IIT2019-20-Zumsteg-HPVOPC: Phase II Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer
๐ฉบ Plain-English Summary (8th-Grade Level)
This study will enroll patients with HPV-associated oropharyngeal cancer, undergoing resection of all gross visible disease at the primary site and in the lymph nodes. A total of 40 patients who have had or will require surgery to remove cancer cells prior to starting chemoradiation may be enrolled. All eligible patients will receive de-intensified cisplatin-based chemoradiation, with high-risk patients receiving a higher dose and longer treatment period than other patients on the study. The study will assess whether a de-intensified version of standard chemoradiation treatment will be just as effective in treating HPV-associated oropharyngeal cancer while causing less side effects than standard dosing.
Who can join: Review the eligibility criteria below.
Location: Tower Hematology-Oncology โ Beverly Hills, California
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (4 Sites)
- Tower Hematology-Oncology โ Beverly Hills, California
- Cedars-Sinai Medical Center (Beverly - Main Site) โ Los Angeles, California
- Valley Oncology Medical Group โ Tarzana, California
- Torrance Memorial Physician Network Cancer Care โ Torrance, California
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV โ Sรฃo Paulo, Sรฃo Paulo
- De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx โ Orange, California
Explore by condition: All HPV Positive Oropharyngeal Squamous Cell Carcinoma clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.